T1	Participants 516 652	outpatients between 4 and 12 years of age with the diagnosis of ADs and a score of more than 12 on Aberrant Behavior Checklist-Community
T2	Participants 728 736	2 groups
T3	Participants 787 798	other group
T4	Participants 808 819	risperidone
T5	Participants 817 833	ne plus placebo.
T6	Participants 757 777	risperidone plus NAC
T7	Participants 846 857	risperidone
T8	Participants 1127 1170	Forty patients completed the 10-week trial.
T9	Participants 1343 1351	2 groups
